Moderna says patent ruling not to affect COVID-19 vaccine development
Moderna Inc said on Friday its formula used in developing a COVID-19 vaccine was not covered under patents owned by Arbutus Biopharma.
Moderna Inc said on Friday its formula used in developing a COVID-19 vaccine was not covered under patents owned by Arbutus Biopharma.
An administrative court run by the U.S. Patent and Trademark Office on Thursday rejected Moderna`s arguments to invalidate a U.S. patent owned by Arbutus, sparking worries over its efforts to develop next-generation vaccines, including a coronavirus vaccine.
See Zee Business Live TV streaming below:
Moderna said the court`s ruling relates to actions it took in response to "longstanding aggressive posture" taken by Arbutus against developers of nucleic acid-based therapeutics and began well before the development of mRNA-1273, its COVID-19 vaccine candidate.
Moderna shares were up slightly in extended trading, while Arbutus shares closed down 20% on Friday.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.